— Know what they know.
Not Investment Advice

RVNC NASDAQ

Revance Therapeutics, Inc.
1W: +0.6% 1M: +5.2% 3M: -37.2% 1Y: -28.4% 3Y: -73.0% 5Y: -84.3%
$3.65
Last traded 2025-02-06 — delisted
NASDAQ · Healthcare · Biotechnology · $381.0M mcap · 91M float · 3.24% daily turnover

📊 Key Metrics

TTM
$247M
Revenue
+15.3% YoY
$-181M
Net Income
+56.7% YoY
$-195M
Free Cash Flow
+15.3% YoY
70.6%
Gross Margin
-53.9%
Op. Margin
-58.6%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE134.8%
ROA-36.5%
ROIC-96.2%

Valuation

P/E-1.0
P/B-2.0
EV/EBITDA-5.6

Leverage

Debt/Equity-2.97
Current Ratio4.12
Interest Cov.-6.8x

Quality Scores

Piotroski F3/9
Altman Z-6.11
Beneish M-1.54

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms